Glenmark Pharmaceuticals Inc., USA launches Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials

Glenmark Pharmaceuticals Inc., USA launches Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials Elmwood Park, New Jersey, June 05, 2026 – Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the launch1 of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials . Glenmark’s Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat®2 Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc. [NDA 022254]. According to IQVIA® sales data for the 12-month period ending April 2026, the Vimpat® Injection market3 achieved annual sales of approximately $15.2 million*. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States. By expanding our injectable product portfolio, we are enhancing our ability to meet the evo lving needs of healthcare providers while advancing our commitment to improving patient access to quality, affordable treatment options.” 1Glenmark’s Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single -Dose Vials is only approved for the indication(s) listed in Glenmark’s approved label. 2All brand names and trademarks are the property of their respective owners. 3Market includes brand and all available therapeutic equivalents. Note: IQVI A® data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for the indications listed in Glenmark’s approved label and is not marketed for all RLD indications. *IQVIA® National Sales Perspectives: Retail & Non-Retail, April 2026 About Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research ‐led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to highquality and affordable medicines for patients around the world. Wi th 11 world -class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com For more information, please contact India United States Akhila Natarajan | [email protected] | +91 22 4018 9999 Adfactors PR | [email protected] | +91 9535635461 Akhila Natarajan | [email protected] Danielle Hagen | [email protected] 202-365-6112

The release as fetched from its publisher. glenmarkpharma.com ↗